Modeling cost-effectiveness and health gains of a "universal" versus "prioritized" hepatitis C virus treatment policy in a real-life cohort.
Loreta Anesti KondiliFederica RomanoFrancesca Romana RolliMatteo RuggeriStefano RosatoMaurizia Rossana BrunettoAnna Linda ZignegoAlessia CiancioAlfredo Di LeoGiovanni RaimondoCarlo FerrariGloria TalianiGuglielmo BorgiaTeresa Antonia SantantonioPierluigi BlancGiovanni Battista GaetaAntonio GasbarriniLuchino ChessaElke Maria ErneErica VillaDonatella IeluzziFrancesco Paolo RussoPietro AndreoneMaria VinciCarmine CoppolaLiliana ChemelloSalvatore MadoniaGabriella VerucchiMarcello PersicoMassimo ZuinMassimo PuotiAlfredo AlbertiGerardo NardoneMarco MassariGiuseppe MontaltoGiuseppe FotiMaria Grazia RumiMaria Giovanna QuarantaAmerico CicchettiAntonio CraxìStefano Vellanull nullPublished in: Hepatology (Baltimore, Md.) (2017)
Extending hepatitis C virus treatment to patients in any fibrosis stage improves health outcomes and is cost-effective; cost-effectiveness significantly increases when lowering treatment prices in early fibrosis stages. (Hepatology 2017;66:1814-1825).